Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Vtrs - You Need To See This

Viatris Stock: Is VTRS Outperforming the Health Care Sector?

As Viatris has outperformed the broader health care sector over the past year, and analysts remain moderately optimistic about the stock’s prospects.

Barchart

What Are Wall Street Analysts' Target Price for Viatris Stock?

Though Viatris has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart

Viatris Earnings Preview: What to Expect

Viatris is set to report its fourth-quarter earnings soon, with analysts forecasting a slight decline in profits.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Viatris Stock Outperforming the Dow?

As Viatris has outperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.

Barchart

Viatris Stock: Is Wall Street Bullish or Bearish?

Viatris has underperformed the broader market in recent months, and analysts’ outlook remains guarded as the company executes on its transformation efforts.

Barchart

What You Need to Know Ahead of Viatris' Earnings Release

Viatris will release its third-quarter earnings next month, and analysts anticipate a double-digit profit dip.

Barchart

Is Viatris Stock Underperforming the Nasdaq?

Viatris has lagged the broader Nasdaq Composite over the past year, and Wall Street sentiment toward the stock remains guarded.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS

In the latest investment moves, Greenlight Capital (NASDAQ:GLRE), led by David Einhorn, has disclosed its Q2 2025 13F filing trades.

Benzinga

Viatris Stock: Analyst Estimates & Ratings

Viatris has considerably underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Barchart

What to Expect From Viatris' Next Quarterly Earnings Report

Viatris is all set to release its fiscal second-quarter earnings next month, and analysts project a double-digit earnings drop.

Barchart

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

As the pharmaceutical industry increasingly focuses on developing targeted treatments for niche conditions, Viatris Inc. (NASDAQ:VTRS) on Friday announced topline data from a Phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis.

Benzinga

Is Viatris Stock Underperforming the S&P 500?

Viatris has significantly underperformed the S&P 500 over the past year, and analysts remain cautious about the stock’s prospects.

Barchart

Do Wall Street Analysts Like Viatris Stock?

Viatris has underperformed the broader market over the past year, and analysts remain skeptical of the stock’s future potential.

Barchart

What to Expect From Viatris' Q1 2025 Earnings Report

Viatris is scheduled to report its first-quarter results next month, and analysts expect a double-digit earnings drop.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

How Is Viatris’ Stock Performance Compared to Other Biotech Stocks?

Over the past six months, Viatris has lagged behind its biotech peers, and Wall Street analysts continue to exercise caution regarding the stock's future outlook.

Barchart

Viatris Stock Outlook: Is Wall Street Bullish or Bearish?

As Viatris has trailed the broader market over the past year, analysts are skeptical about its future outlook.

StockNews.com

3 Hidden Bargains in the Healthcare Sector

Healthcare’s resilience makes it a go-to sector during market volatility. With steady demand, innovation, and aging demographics driving growth, investors could consider investing in fundamentally sound stocks like Viatris (VTRS), Bausch + Lomb Corp. (BLCO), and ACADIA Pharmaceuticals (ACAD). With strong industry tailwinds and discounted valuations, these stocks could offer…

Barchart

Viatris Stock: Is VTRS Outperforming the Healthcare Sector?

Despite Viatris’ recent outperformance relative to its broader sector, Wall Street analysts remain cautious about the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Are Wall Street Analysts Predicting Viatris Stock Will Climb or Sink?

Due to Viatris’ underperformance relative to the broader S&P 500 Index over the past year, Wall Street analysts remain cautious about the stock’s prospects.

Barchart

Earnings Preview: What to Expect From Viatris' Report

Viatris is all set to announce its third-quarter results next month, with analysts predicting a double-digit decline in the company's earnings.

Barchart

Is Viatris Stock Underperforming the Dow?

Viatris has underperformed the Dow Jones Industrial Average over the past year, and analysts remain cautious about the stock’s prospects.

Barchart

Is Wall Street Bullish or Bearish on Viatris' Stock?

Viatris has underperformed the broader market over the past year, and Wall Street analysts are cautious about the stock’s prospects.

Barchart

Viatris Quarterly Earnings Preview: What You Need to Know

Viatris is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.

StockNews.com

3 Low P/E Stocks With Strong Growth Prospects

With easing inflation and possibilities of interest rate cuts, investors can rely on stocks like Viatris (VTRS), Open Text (OTEX), and Goodyear Tire & Rubber (GT) with strong growth prospects, trading at affordable prices. Keep reading.

StockNews.com

3 Pharmaceutical Stocks With Blockbuster Potential

The pharmaceutical industry’s long-term growth is fueled by a surge in demand for personalized medicine, favorable R&D initiatives, and the adoption of cutting-edge technologies. Hence, it could be ideal to buy fundamentally solid pharma stocks Zoetis (ZTS), Viatris (VTRS), and Bristol-Myers Squibb (BMY) poised for blockbuster return potential. Keep reading….

1 2

People

David Einhorn

16 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

BristolMyers Squibb Company

Open Text Corporation

17 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.